EFFECTS OF DOSE, PH AND OSMOLARITY ON INTRANASAL ABSORPTION OF RECOMBINANT-HUMAN-ERYTHROPOIETIN IN RATS

被引:0
作者
SHIMODA, N [1 ]
MAITANI, Y [1 ]
MACHIDA, Y [1 ]
NAGAI, T [1 ]
机构
[1] CHUGAI PHARMACEUT CO LTD, DEPT BUSINESS COORDINAT, DIV DEV & TECHNOL, KITA KU, TOKYO 115, JAPAN
关键词
ERYTHROPOIETIN; INTRANASAL ADMINISTRATION; GLYCOPROTEIN CIRCULATING RETICULOCYTE; BIOAVAILABILITY;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of dose, pH and osmolarity on the intranasal absorption of a recombinant human erythropoietin (rEPO) solution were studied in male Wistar rats, The intranasal administration of rEPO was evaluated by measuring percentage circulating reticulocytes of red blood cells on a stained blood smear (smear method), and also by measuring residual circulating reticulocyte counts using a microcell counter (sysmex method), Both results suggest that rEPO solution was absorbed through the nasal mucosa of rats without enhancers after a single intranasal administration, The pharmacological availabilities of rEPO after intranasal administration compared with intravenous administration were about 7% and 4%, when estimated by smear method and sysmex method, respectively, The pharmacological activity was enhanced in low pH and hypotonic mannitol solution.
引用
收藏
页码:734 / 739
页数:6
相关论文
共 50 条
[41]   PHARMACOKINETICS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN IN CHILDREN WITH RENAL-FAILURE [J].
EVANS, JHC ;
BROCKLEBANK, JT ;
BOWMER, CJ ;
NG, PC .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1991, 6 (10) :709-714
[42]   RECOMBINANT-HUMAN-ERYTHROPOIETIN THERAPY IN THE SURGICAL SETTING AND APPLICATIONS IN ONCOLOGY [J].
GOODNOUGH, LT .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1991, 18 (04) :98-102
[43]   RECOMBINANT-HUMAN-ERYTHROPOIETIN IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES - RESPONSE PATTERNS [J].
LEWINSKI, UH ;
FLORU, S ;
COHEN, AM ;
MITTELMANN, M .
LEUKEMIA & LYMPHOMA, 1994, 15 (1-2) :149-152
[44]   INFLUENCE OF THALASSEMIA ON THE RESPONSE TO RECOMBINANT-HUMAN-ERYTHROPOIETIN IN DIALYSIS PATIENTS [J].
CHENG, IKP ;
LU, HB ;
WEI, DCC ;
CHENG, SW ;
CHAN, CY ;
LEE, FCP .
AMERICAN JOURNAL OF NEPHROLOGY, 1993, 13 (02) :142-148
[45]   THE TREATMENT OF RENAL ANEMIA IN CAPD PATIENTS WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN [J].
MACDOUGALL, IC ;
DAVIES, ME ;
HUTTON, RD ;
CAVILL, I ;
LEWIS, NP ;
COLES, GA ;
WILLIAMS, JD .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1990, 5 (11) :950-955
[46]   PRACTICAL APPROACH TO INITIATION OF RECOMBINANT-HUMAN-ERYTHROPOIETIN THERAPY AND PREVENTION AND MANAGEMENT OF ADVERSE-EFFECTS [J].
ABRAHAM, PA .
AMERICAN JOURNAL OF NEPHROLOGY, 1990, 10 :7-14
[47]   THE EFFECT OF RECOMBINANT-HUMAN-ERYTHROPOIETIN ON HEMOSTATIC STATUS IN CHRONIC UREMIC PATIENTS [J].
TSAO, CJ ;
KAO, RH ;
CHENG, TY ;
HUANG, CC ;
CHANG, SL ;
LEE, FN .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 1992, 55 (02) :197-203
[48]   EFFECTS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN AND INTERLEUKIN-3 ON ERYTHROPOIETIC RECOVERY FROM ACUTE ANEMIA [J].
ROSEN, BS ;
LEVINE, EA ;
EGRIE, JC ;
SEHGAL, LR ;
GREENBERG, R ;
ROSEN, AL ;
LEVINE, HD ;
GOULD, SA .
EXPERIMENTAL HEMATOLOGY, 1993, 21 (11) :1487-1491
[49]   EFFECT OF HEMODIALYSIS AND RECOMBINANT-HUMAN-ERYTHROPOIETIN ON DETERMINANTS OF BLOOD-VISCOSITY [J].
SHAND, BI ;
BUTTIMORE, AL ;
LYNN, KL ;
BAILEY, RR ;
ROBSON, RA .
RENAL FAILURE, 1994, 16 (03) :407-413
[50]   EVIDENCE-BASED RECOMMENDATIONS FOR THE CLINICAL USE OF RECOMBINANT-HUMAN-ERYTHROPOIETIN [J].
MUIRHEAD, N ;
BARGMAN, J ;
BURGESS, E ;
JINDAL, KK ;
LEVIN, A ;
NOLIN, L ;
PARFREY, P .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 26 (02) :S1-S24